Keywords: |
neutropenia; conference paper; antineoplastic agent; neoplasms; cancer immunotherapy; myalgia; granulocyte macrophage colony stimulating factor; bone pain; hypotension; recombinant proteins; interleukin 6; granulocyte colony stimulating factor; granulocyte colony-stimulating factor; colony-stimulating factors; intravenous drug administration; colony stimulating factor 1; interleukin 1; drug interaction; growth substances; granulocyte-macrophage colony-stimulating factor; interleukin 3; subcutaneous drug administration; human; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
|